Prospective Longitudinal Observational Research in Atopic Dermatitis (ProRaD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04240522|
Recruitment Status : Recruiting
First Posted : January 27, 2020
Last Update Posted : January 27, 2020
Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march.
Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality.
This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new and individual treatment options of atopic diseases.
|Condition or disease|
|Https://Meshb.Nlm.Nih.Gov/Record/ui?ui=D003876 Atopic Dermatitis Asthma Atopic Dermatitis and Related Conditions|
In the planned project, the main objective is to identify endogenous (e.g. immunological and molecular factors) and exogenous factors (e.g. environmental, socioeconomic and microbial factors) that influence the course and remission of AD. More specifically to identify factors that are significantly different between patients that have or do not have remission from AD.
(i) To identify endogenous and exogenous factors such as immunological, molecular and microbial factors to separate subgroups of patients (endotypes) with distinct local and systemic inflammatory responses.
(ii) To identify potential biomarkers predicting the individual clinical course of AD and other atopic diseases including asthma, food allergy and allergic rhinitis.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Prospective Longitudinal Observational Research Study to Investigate the Remission of Atopic Dermatitis and Associated Allergic Diseases|
|Actual Study Start Date :||April 4, 2017|
|Actual Primary Completion Date :||January 20, 2020|
|Estimated Study Completion Date :||April 4, 2024|
- Remission of atopic dermatitis and associated allergic diseases [ Time Frame: 5 years ]Prospective observational study
- Endogenous and exgogenouse factors that influence and predict the cours of AD. [ Time Frame: 5 years ]SCORAD
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04240522
|Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich||Recruiting|
|Zürich, Switzerland, 8091|
|Contact: Peter Schmid-Grendelmeier, Prof, MD +41442553079 firstname.lastname@example.org|